WALTHAM, Mass.--(BUSINESS WIRE
News
RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types
Research Triangle Park, NC, USA and Cambridge, UK, 29 October 2020 – Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program candidate.
• Announcing the challenge
This week the 7th CSP Blind Test begins - a major challenge in computational chemistry. It will see the world leading methods in Crystal Structure Prediction put to the test on real targets - with a high bar set by previous work. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.
• The importance of CSP
The 3D structure and packing of crystalline materials have a big impact on their properties - this is most relevant in drug discovery and development.
The DimAb™ development platform is different from traditional hybridoma fusion technologies in that it can directly isolate IgG genes from B cells of immunized animals. Using this novel platform - a number of custom development projects have already been completed with high customer satisfaction.
London and Cambridge, October 20, 2020 - Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.
Westbury, NY – Oct. 19, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its HEPATOMUNE® kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury.
AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.
New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment
Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).1
Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.